SANDOSTATIN

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Length of Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandostatin</td>
<td>Octreotide Acetate</td>
<td>3 Months</td>
</tr>
<tr>
<td>Sandostatin LAR Depot</td>
<td>Octreotide Acetate</td>
<td>3 Months</td>
</tr>
</tbody>
</table>

**Approvable Criteria:**
Is the member diagnosed with one of the following conditions?
- Acromegaly.
- Carcinoid Tumor.
- VI Poma (vasoactive intestinal peptide tumor).
- GI Fistula.
  - If yes, approve for 3 months.
  - If no, do not approve.

**SQ (not LAR) = SELF-ADMINISTERED – RX ONLY
SPECIALTY PHARMACY PRODUCT**

**FDA Approved Indications:**
**Acromegaly:** To reduce blood levels of growth hormone and IGF-I in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation and bromocriptine at maximally tolerated doses.

**Carcinoid tumors:** Symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits associated severe diarrhea and flushing episodes.

**Vasoactive intestinal peptide tumors (VI Pomas):** Treatment of the profuse watery diarrhea associated with VIP-secreting tumors.

**VI Pomas:** For treatment of the profuse watery diarrhea associated with VIP-secreting tumors.

**GI fistula:** To reduce output from GI fistulas.

**Sandostatin LAR Depot:**
**Acromegaly** – For long-term maintenance therapy in acromegalic patients for whom medical treatment is appropriate and who have been shown to respond to and can tolerate octreotide acetate injection. The goal of treatment in acromegaly is to reduce GH and IGF-I levels to normal. Sandostatin LAR Depot can be used in patients who have had an inadequate response to surgery or in those for whom surgical resection is not an option. It may also be used in patients who have received radiation and have had an inadequate therapeutic response.

**Carcinoid tumors** – For long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors in patients in whom initial treatment with Sandostatin injection has been shown to be effective and tolerated.

**VIPomas** – For long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with Sandostatin injection has been shown to be effective and tolerated.

**References:**
- Sandostatin prescribing information 2000.
- Sandostatin LAR Depot prescribing information 2003.